Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651385 | 0.86 | PKM (0.58) | L3MBTL1KMT2ANPC1RAB9AKCNK3 | |
| SCHEMBL7186209 | 0.86 | KCNK3 (0.71) | L3MBTL1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL30440532 | 0.86 | KCNK3 (0.71) | L3MBTL1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL15652600 | 0.85 | NPC1 (0.57) | L3MBTL1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL15651539 | 0.85 | KMT2A (0.62) | L3MBTL1KMT2ANPC1RAB9AKCNK3 | |
| SCHEMBL15652954 | 0.85 | MEN1 (0.73) | L3MBTL1KMT2ANPC1RAB9AKCNK3 | |
| SCHEMBL29572557 | 0.85 | MEN1 (0.73) | L3MBTL1KMT2ANPC1RAB9AKCNK3 | |
| SCHEMBL17095034 | 0.85 | PKM (0.54) | L3MBTL1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL15651395 | 0.84 | NPC1 (0.56) | L3MBTL1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL13917760 | 0.84 | PKM (0.59) | L3MBTL1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | disclosed |
| US-20150336893-A1 | 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-26 | — | — | US | disclosed |
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-1746097-B1 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | AVENTIS PHARMA SA (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1910366-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| EP-1746097-A1 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | DPYD, DHPS, QDPR | L3MBTL1 4878/4885KMT2A 3525/4885NPC1 400/4885 |
| US-20150336893-A1 | 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives | CXCR1, CXCR5, CXCR4 | L3MBTL1 4302/4885KMT2A 1644/4885NPC1 1084/4885 |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | CXCR1, CXCR5, CXCR4 | L3MBTL1 4525/4885KMT2A 1884/4885NPC1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.